Abstract
Definitive concurrent chemoradiotherapy (CCRT) has become the standard of care in patients (pts) with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). However, some patients still experience local failure or distant metastasis. The PACIFIC study has confirmed that consolidation immunotherapy with durvalumab significantly improves the progression-free survival (PFS) and overall survival (OS) for patients with unresectable, stage III non small cell lung cancer (NSCLC) after CCRT, but the efficacy of consolidation immunotherapy for unresectable esophageal cancer is unclear.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.